Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas

Cory D. Rillahan, Matthew S. Macauley, Erik Schwartz, Yuan He, Ryan McBride, Britni M. Arlian, Janani Rangarajan, Valery V. Fokin, James C. Paulson

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

The siglec family of sialic acid-binding proteins are endocytic immune cell receptors that are recognized as potential targets for cell directed therapies. CD33 and CD22 are prototypical members and are validated candidates for targeting acute myeloid leukaemia and non-Hodgkin's lymphomas due to their restricted expression on myeloid cells and B-cells, respectively. While nanoparticles decorated with high affinity siglec ligands represent an attractive platform for delivery of therapeutic agents to these cells, a lack of ligands with suitable affinity and/or selectivity has hampered progress. Herein we describe selective ligands for both of these siglecs, which when displayed on liposomal nanoparticles, can efficiently target the cells expressing them in peripheral human blood. Key to their identification was the development of a facile method for chemo-enzymatic synthesis of disubstituted sialic acid analogues, combined with iterative rounds of synthesis and rapid functional analysis using glycan microarrays. This journal is

Original languageEnglish
Pages (from-to)2398-2406
Number of pages9
JournalChemical Science
Volume5
Issue number6
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

Sialic Acid Binding Immunoglobulin-like Lectins
N-Acetylneuraminic Acid
Cells
Ligands
Nanoparticles
Functional analysis
Microarrays
Polysaccharides
Carrier Proteins
Blood

ASJC Scopus subject areas

  • Chemistry(all)

Cite this

Rillahan, C. D., Macauley, M. S., Schwartz, E., He, Y., McBride, R., Arlian, B. M., ... Paulson, J. C. (2014). Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. Chemical Science, 5(6), 2398-2406. https://doi.org/10.1039/c4sc00451e

Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. / Rillahan, Cory D.; Macauley, Matthew S.; Schwartz, Erik; He, Yuan; McBride, Ryan; Arlian, Britni M.; Rangarajan, Janani; Fokin, Valery V.; Paulson, James C.

In: Chemical Science, Vol. 5, No. 6, 2014, p. 2398-2406.

Research output: Contribution to journalArticle

Rillahan, CD, Macauley, MS, Schwartz, E, He, Y, McBride, R, Arlian, BM, Rangarajan, J, Fokin, VV & Paulson, JC 2014, 'Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas', Chemical Science, vol. 5, no. 6, pp. 2398-2406. https://doi.org/10.1039/c4sc00451e
Rillahan, Cory D. ; Macauley, Matthew S. ; Schwartz, Erik ; He, Yuan ; McBride, Ryan ; Arlian, Britni M. ; Rangarajan, Janani ; Fokin, Valery V. ; Paulson, James C. / Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas. In: Chemical Science. 2014 ; Vol. 5, No. 6. pp. 2398-2406.
@article{fa2cee01ffe94e0287e2a15dc10a3a4e,
title = "Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas",
abstract = "The siglec family of sialic acid-binding proteins are endocytic immune cell receptors that are recognized as potential targets for cell directed therapies. CD33 and CD22 are prototypical members and are validated candidates for targeting acute myeloid leukaemia and non-Hodgkin's lymphomas due to their restricted expression on myeloid cells and B-cells, respectively. While nanoparticles decorated with high affinity siglec ligands represent an attractive platform for delivery of therapeutic agents to these cells, a lack of ligands with suitable affinity and/or selectivity has hampered progress. Herein we describe selective ligands for both of these siglecs, which when displayed on liposomal nanoparticles, can efficiently target the cells expressing them in peripheral human blood. Key to their identification was the development of a facile method for chemo-enzymatic synthesis of disubstituted sialic acid analogues, combined with iterative rounds of synthesis and rapid functional analysis using glycan microarrays. This journal is",
author = "Rillahan, {Cory D.} and Macauley, {Matthew S.} and Erik Schwartz and Yuan He and Ryan McBride and Arlian, {Britni M.} and Janani Rangarajan and Fokin, {Valery V.} and Paulson, {James C.}",
year = "2014",
doi = "10.1039/c4sc00451e",
language = "English",
volume = "5",
pages = "2398--2406",
journal = "Chemical Science",
issn = "2041-6520",
publisher = "Royal Society of Chemistry",
number = "6",

}

TY - JOUR

T1 - Disubstituted sialic acid ligands targeting siglecs CD33 and CD22 associated with myeloid leukaemias and B cell lymphomas

AU - Rillahan, Cory D.

AU - Macauley, Matthew S.

AU - Schwartz, Erik

AU - He, Yuan

AU - McBride, Ryan

AU - Arlian, Britni M.

AU - Rangarajan, Janani

AU - Fokin, Valery V.

AU - Paulson, James C.

PY - 2014

Y1 - 2014

N2 - The siglec family of sialic acid-binding proteins are endocytic immune cell receptors that are recognized as potential targets for cell directed therapies. CD33 and CD22 are prototypical members and are validated candidates for targeting acute myeloid leukaemia and non-Hodgkin's lymphomas due to their restricted expression on myeloid cells and B-cells, respectively. While nanoparticles decorated with high affinity siglec ligands represent an attractive platform for delivery of therapeutic agents to these cells, a lack of ligands with suitable affinity and/or selectivity has hampered progress. Herein we describe selective ligands for both of these siglecs, which when displayed on liposomal nanoparticles, can efficiently target the cells expressing them in peripheral human blood. Key to their identification was the development of a facile method for chemo-enzymatic synthesis of disubstituted sialic acid analogues, combined with iterative rounds of synthesis and rapid functional analysis using glycan microarrays. This journal is

AB - The siglec family of sialic acid-binding proteins are endocytic immune cell receptors that are recognized as potential targets for cell directed therapies. CD33 and CD22 are prototypical members and are validated candidates for targeting acute myeloid leukaemia and non-Hodgkin's lymphomas due to their restricted expression on myeloid cells and B-cells, respectively. While nanoparticles decorated with high affinity siglec ligands represent an attractive platform for delivery of therapeutic agents to these cells, a lack of ligands with suitable affinity and/or selectivity has hampered progress. Herein we describe selective ligands for both of these siglecs, which when displayed on liposomal nanoparticles, can efficiently target the cells expressing them in peripheral human blood. Key to their identification was the development of a facile method for chemo-enzymatic synthesis of disubstituted sialic acid analogues, combined with iterative rounds of synthesis and rapid functional analysis using glycan microarrays. This journal is

UR - http://www.scopus.com/inward/record.url?scp=84900346441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900346441&partnerID=8YFLogxK

U2 - 10.1039/c4sc00451e

DO - 10.1039/c4sc00451e

M3 - Article

VL - 5

SP - 2398

EP - 2406

JO - Chemical Science

JF - Chemical Science

SN - 2041-6520

IS - 6

ER -